scholarly journals Pharmacokinetics and safety of paclitaxel delivery into porcine airway walls by a new endobronchial drug delivery catheter

Respirology ◽  
2017 ◽  
Vol 23 (4) ◽  
pp. 399-405 ◽  
Author(s):  
Hisashi Tsukada ◽  
Plamena Entcheva-Dimitrov ◽  
Armin Ernst ◽  
Samaan Rafeq ◽  
John H. Keating ◽  
...  
2020 ◽  
Vol 96 (2) ◽  
pp. 393-401 ◽  
Author(s):  
Frank Bunch ◽  
Pradeep Nair ◽  
Gaurav Aggarwala ◽  
Eric Dippel ◽  
Elias Kassab ◽  
...  

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 85A
Author(s):  
Hisashi Tsukada ◽  
Plamena Entcheva-Dimitrov ◽  
Kirk Seward ◽  
Samaan Rafeq ◽  
Armin Ernst

Neurosurgery ◽  
2003 ◽  
Vol 52 (5) ◽  
pp. 1169-1177 ◽  
Author(s):  
Phillip B. Storm ◽  
Richard E. Clatterbuck ◽  
Ya J. Liu ◽  
Randolph M. Johnson ◽  
Edward M. Gillis ◽  
...  

2015 ◽  
Vol 22 (4) ◽  
pp. 312-318 ◽  
Author(s):  
Hisashi Tsukada ◽  
Kirk P. Seward ◽  
Samaan Rafeq ◽  
Olivier Kocher ◽  
Armin Ernst

Author(s):  
Sunandita Sarker ◽  
Yiannis S. Chatzizisis ◽  
Srivatsan Kidambi ◽  
Benjamin S. Terry

Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations have confirmed that atherosclerosis is an inflammatory disease [3] [4] [5]. This confirmation has opened the treatment of this disease to many novel anti-inflammatory therapeutics. The use of nanoparticle-nanomedicines has gained popularity over recent years. Initially approved as anticancer treatment therapeutics [6], nanomedicine also holds promise for anti-inflammatory treatment, personalized medicine, target-specific treatment, and imaging of atherosclerotic disease [7]. The primary aim of this collaborative work is to develop and validate a novel strategy for catheter-directed local treatment of high-risk plaque using anti-inflammatory nanoparticles. Preselected drugs with the highest anti-inflammatory efficacy will be incorporated into a novel liposome nanocarrier, and delivered in-vivo through a specially designed catheter to high-risk atherosclerotic plaques. The catheter has specially designed perfusion pores that inject drug into the blood stream in such a controlled manner that the streamlines carry the nanoparticles to the stenotic arterial wall. Once the particles make it to the arterial wall, they can be absorbed into the inflamed tissue. In this paper, we discuss the design and development of an atraumatic drug delivery catheter for the administration of lipid nanoparticles.


CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 421A
Author(s):  
Kirk P. Seward ◽  
Hisashi Tsukada ◽  
Robert E. Garland ◽  
Olivier Kocher ◽  
Armin Ernst

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 420A
Author(s):  
Kirk P. Seward ◽  
Hisashi Tsukada ◽  
Robert E. Garland ◽  
Olivier Kocher ◽  
Armin Ernst

Sign in / Sign up

Export Citation Format

Share Document